Product
ONL1204
Aliases
ONL1204 Ophthalmic solution, ONL1204 Ophthalmic Solution
4 clinical trials
3 indications
Indication
Geographic AtrophyIndication
Rhegmatogenous Retinal DetachmentIndication
GlaucomaClinical trial
A Phase 1b Multicenter, Randomized, Controlled, Single-dose Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Geographic Atrophy (GA) Associated With Age-related Macular Degeneration (AMDStatus: Completed, Estimated PCD: 2024-02-29
Clinical trial
A Phase 2, Randomized, Sham-Controlled, Single-Masked, Dose-Ranging, Multi-Center Study to Assess the Safety and Efficacy of Intravitreal ONL1204 Ophthalmic Solution in Subjects With Macula-off Rhegmatogenous Retinal DetachmentStatus: Completed, Estimated PCD: 2024-02-21
Clinical trial
A Phase 1 Open-Label, Dose Escalation Study to Assess the Safety and Tolerability of Intravitreal ONL1204 in Patients With Macula-off, Rhegmatogenous Retinal DetachmentStatus: Completed, Estimated PCD: 2021-08-24
Clinical trial
A Phase 1b Multicenter, Randomized, Single-Masked, Sham-Controlled Study of the Safety and Tolerability of ONL1204 Ophthalmic Solution in Patients With Progressing Open Angle GlaucomaStatus: Active (not recruiting), Estimated PCD: 2024-04-01